ClearPoint Neuro, Inc. (NASDAQ: CLPT) is a Healthcare company (Medical - Devices) with a market capitalization of $252M. The Maz Rating grades it against the other companies in its sector.
ClearPoint Neuro, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.86, ClearPoint Neuro, Inc. trades at 5.6x sales and 9.0x book value. Over the last twelve months it generated about $45M of revenue and a net loss of $38M. It runs a gross margin of 61.4%, an operating margin of -70.6% and a net margin of -79.4%. It shows return on equity of -170.2%, return on invested capital of -31.1% and a free cash flow yield of -13.2%. On the balance sheet: a debt-to-equity ratio of 2.70 and a current ratio of 6.76. Over the past 52 weeks the share price ranged from $7.81 to $19.63, with a beta of 1.36.
ClearPoint Neuro, Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, ClearPoint Neuro, Inc. (CLPT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 14.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 13.0% / 30% · Interest income / Revenue 2.42% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 14.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.8% / 33% · Receivables / Mkt Cap (36m) 2.51% / 49% · Interest income / Revenue 2.42% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 14.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.8% / 33.33% · Receivables / Mkt Cap (24m) 2.51% / 33.33% · Interest income / Revenue 2.42% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 51.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 40.2% / 33.33% · Receivables / Avg Assets (4Q) 8.80% / 33.33% · Interest income / Revenue 2.42% / 5% | Fail |
| FTSE | Debt / Total Assets 45.1% / 33.33% · (Cash+ST Inv) / Total Assets 41.0% / 33.33% · (Cash+Recv) / Total Assets 49.0% / 33.33% · Interest income / Revenue 2.42% / 5% | Fail |
It depends on the standard you follow. As of September 2026, ClearPoint Neuro, Inc. (CLPT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. ClearPoint Neuro, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.42% of each dividend: ClearPoint Neuro, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.